Lilly claims the weight-loss drug reduced the risk of heart failure by 38 per cent in trials
Trial results show that Eli Lilly’s weight-loss drug Zepbound reduces the risk of hospitalisation, death and other outcomes for adults with obesity and a common type of heart failure, the company said on Thursday, continuing to gather evidence of the drug’s broader health benefits.
BELIEBTE BEITRÄGE
Poland prepares for peaking floods
September 20, 2024
Italy evacuates thousands as Boris hits the north
September 20, 2024
China and the US race to tame nuclear fusion for clean energy
September 20, 2024
LIVEÜBERTRAGUNG